Comparing Stevanato Group (NYSE:STVN) & Galectin Therapeutics (NASDAQ:GALT)

Galectin Therapeutics (NASDAQ:GALT) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and target prices for Galectin Therapeutics and Stevanato Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1	0	1	0	2.00
Stevanato Group	0	2	2	2	3.00

Galectin Therapeutics presently has a consensus price target of $11.00, indicating a potential upside of 143.90%. Given Galectin Therapeutics’ higher possible upside, research analysts clearly believe Galectin Therapeutics is more favorable than Stevanato Group.

Volatility & Risk

Galectin Therapeutics has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.

Valuation and Earnings

This table compares Galectin Therapeutics and Stevanato Group”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84 million	($0.41)	-11.00
Stevanato Group	$1.34 billion	4.28	$158.21 million	€0.59	32.18

Stevanato Group has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Galectin Therapeutics and Stevanato Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-164.69%
Stevanato Group	11.76%	10.27%	6.08%

Insider and Institutional Ownership

11.7% of Galectin Therapeutics shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by insiders. Comparatively, 0.7% of Stevanato Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Stevanato Group beats Galectin Therapeutics on 11 of the 14 factors compared between the two stocks.

About Galectin Therapeutics

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.